Pasar al contenido principal

CONTROLANDO PERFILES DE SEÑALIZACION DE GPCRS PARA SU USO EN EL TRATAMIENTO DE NEUROPATOLOGIAS

PID2023-148739NB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2023
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario UNIVERSIDAD DE ZARAGOZA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

FDA Drug Repurposing Uncovers Modulators of Dopamine D2 Receptor Localization via Disruption of the NCS-1 Interaction

  • Muñoz-Reyes, Daniel
  • Aguado, Lorena
  • Arroyo-Urea, Sandra
  • Requena, Carlos
  • Pérez-Suárez, Sara
  • Sánchez-Yepes, Sonia
  • Argerich, Josep
  • Miró-Rodríguez, Celia
  • Ulzurrun, Eugenia
  • Rodríguez-Martín, Eulalia
  • García-Nafría, Javier
  • Campillo, Nuria E.
  • Mansilla, Alicia
  • Sánchez-Barrena, María José
Dopamine D2 receptor (D2 R) regulates key aspects of motor control, cognition, and reward. Its function depends not only on ligand binding and signaling efficacy but also on the dynamic control of receptor localization at the cell surface. Neuronal calcium sensor 1 (NCS-1) interacts with D2 R in a Ca2+ -dependent manner. Using in vitro and cellular assays, we found that NCS-1 promotes D2 R trafficking to the plasma membrane through active exocytosis while preserving canonical receptor pharmacology. A screen of FDA-approved drugs identified protein–protein interaction (PPI) modulators targeting the NCS-1/D2 R interface. Azilsartan medoxomil, atorvastatin, and vilazodone disrupt this interaction, reducing D2 R surface expression. Structural studies revealed that these compounds target NCS-1, overlap the D2 R binding site, and perturb the dynamics of the regulatory helix H10. These findings reveal an unexploited intracellular mechanism to modulate D2 R function via PPI modulation, offering a novel strategy to fine-tune dopaminergic tone beyond receptor blockade or direct agonism., This work was supported by grants PID2019-111737RB-I00 and PID2022-137331OB-C31 (to M.J.S.B.); PID2020 113359GA-I00 and PID2023-148739NB-I00 (to J.G.N.);PID2022-137331OB-C32 (to A.M.); PID2022-137331OB-C33 (to N.E.C.); and the Spanish “Ramón y Cajal” program (to J.G.N. and A.M.), which were funded by the MICIU/AEI/ 10.13039/501100011033, FEDER and EU. S.P.S. was supported by a contract from the “Programa de Empleo Juvenil de la Comunidad de Madrid” PEJ-2020-AI/BMD 18666 and CMR by a Spanish National Research Council JAE Intro grant (JAEINT_23_00101)., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Constitutively active orphan G protein-coupled receptors through the lenses of cryo-electron microscopy

  • Argerich, Josep
  • Muñoz-Reyes, Daniel
  • Val-García, Iris del
  • García-Nafría, Javier
G protein-coupled receptors (GPCRs) are a therapeutically privileged family of receptors involved in a wide variety of pathophysiological conditions and the successful target for ∼34% of FDA-approved drugs. However, a significant percentage of GPCRs remain orphan, i.e., the endogenous ligands that modulate receptor function are unknown, and hence knowledge about their functional role and the generation of new therapeutics lag behind. During recent years, the use of cryo-electron microscopy has revolutionized GPCR structural biology including its application to orphan GPCRs, especially those displaying constitutive activity in cellular model systems. Such efforts have resulted in the description of new modes of in-built agonists that include the ECL2 and N-terminal regions as well as identifying ubiquitous endogenous ligands readily bound to GPCRs. These results position structural determination as a new key component in GPCR deorphanization, shedding light on new signaling mechanisms, bringing questions about their functional regulation, and opening new avenues for drug design.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

FDA Drug Repurposing Uncovers Modulators of Dopamine D<sub>2</sub> Receptor Localization via Disruption of the NCS-1 Interaction

  • Muñoz-Reyes, Daniel
  • Aguado, Lorena
  • Arroyo-Urea, Sandra
  • Requena, Carlos
  • Pérez-Suárez, Sara
  • Sánchez-Yepes, Sonia
  • Argerich, Josep
  • Miró-Rodríguez, Celia
  • Ulzurrun, Eugenia
  • Rodríguez-Martín, Eulalia
  • García-Nafría, Javier
  • Campillo, Nuria E.
  • Mansilla, Alicia
  • Sánchez-Barrena, María José
Dopamine D2 receptor (D2R) regulates key aspects of motor control, cognition, and reward. Its function depends not only on ligand binding and signaling efficacy but also on the dynamic control of receptor localization at the cell surface. Neuronal calcium sensor 1 (NCS-1) interacts with D2R in a Ca2+-dependent manner. Using in vitro and cellular assays, we found that NCS-1 promotes D2R trafficking to the plasma membrane through active exocytosis while preserving canonical receptor pharmacology. A screen of FDA-approved drugs identified protein–protein interaction (PPI) modulators targeting the NCS-1/D2R interface. Azilsartan medoxomil, atorvastatin, and vilazodone disrupt this interaction, reducing D2R surface expression. Structural studies revealed that these compounds target NCS-1, overlap the D2R binding site, and perturb the dynamics of the regulatory helix H10. These findings reveal an unexploited intracellular mechanism to modulate D2R function via PPI modulation, offering a novel strategy to fine-tune dopaminergic tone beyond receptor blockade or direct agonism.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

A Ligand-Triggered Receptor Conformation Enables the Design of Selective Agonists for the Dopamine 3 Receptor (D <sub>3</sub> R) Using a Bitopic Strategy

  • Arroyo-Urea, Sandra
  • Nazarova, Antonina L.
  • Knieb, Alexander
  • Abdulsalam, Hawau
  • Jahan, Khorshada
  • Du, Ting
  • Gao, Song
  • Newman, Amy Hauck
  • Katritch, Vsevolod
  • García-Nafría, Javier
  • Bonifazi, Alessandro
While G protein-coupled receptors (GPCRs) represent the largest drug target family, designing subtype-selective molecules is still a challenge, especially to distinguish among closely related subtypes. One of the most challenging cases is the distinction between dopamine D2R and D3R, pivotal receptors in motor functions and cognition, and targets of Parkinson’s disease treatments, schizophrenia, or substance use disorders. Attempts to design D3R-selective molecules with ligands binding toward the first transmembrane helix (the most sequence-diverse and conformationally flexible segment in GPCRs but rarely participating in ligand binding) allowed us to discover a ligand-induced ordering of TM1 unique to D3R, yielding an unexploited selectivity site for drug development. Using rational bitopic drug design and the ligand-triggered conformation of the D3R we designed, synthesized, and characterized the most selective D3R agonists to date, >100,000-fold more selective than available ligands. More specifically, we report D3R partial agonists AB12-82 (6d) and AB13-73A (11), with >575,000- and >750,000-fold subtype selectivity, picomolar potency, and 85% and 49% efficacy, respectively. We also present the most selective full agonists reported to date, AB13-08 (4b) and AB13-46A (9), presenting low and subnanomolar potencies with >2,800- and 6,300-fold selectivity for D3R. Overall, we introduce a first-in-class pharmacological toolbox to dissect the (patho)-physiology of D3R, open new avenues for the design of improved neurotherapeutics, and show that using ligand-induced TM1 reorganizations might represent a promising strategy for the design of subtype-selective molecules in other GPCRs.